Clinical Trial Detail

NCT ID NCT02422615
Title Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Ribociclib

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST